

Our Ref: 65/2022  
JANUARY 2022

## Re: Your request made under the Freedom of Information Act 2000

I am analysing the usage of new biologic medications for the treatment of dermatological conditions. I would greatly appreciate if you could answer the following question.

How many patients were treated in January 2022 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibinqo) **0**
- Baricitinib (Olumiant) **0**
- Bimekizumab (Bimzelx) **0**
- Brodalumab (Kyntheum) **4**
- Dupilumab (Dupixent) **6**
- Ixekizumab (Taltz) **2**
- Risankizumab (Skyrizi) **0**
- Guselkumab (Tremfya) **4**
- Secukinumab (Cosentyx) **15**
- Tildrakizumab (Ilumetri) **1**
- Tralokinumab (Adtralza) **0**
- Upadacitinib (Rinvoq) **0**
- Ustekinumab (Stelara) **6**